A New Era in Lipid Lowering Therapy: An update on PCSK9 Inhibition


Related Videos (49)

In this video, Dean Karalis, MD, delves into a chief concern for preventive cardiologists-the effort to lower lipid levels and thereby reduce the risk of cardiovascular disease. A preventive cardiologist, Dr. Karalis describes the pathogenesis of atherosclerosis, and the present and future agents in place to lower lipid levels, describing first the mechanisms, concerns and issues identified with the statins, and the approach of the recently approved PCSK9 inhibitor alirocumab. A natural occurring protein, PCSK9 binds to the low-density lipoprotein receptor to promote its degradation in the liver. Dr. Karalis discusses this mechanism, findings from the pre-approval studies for alirocumab and the indications for the drug.


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®